Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. 1988

Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
Department of Biopharmaceutics and Pharmacokinetics, University of Uppsala, Sweden.

The clinical pharmacokinetics of clozapine, an atypical neuroleptic, was evaluated in 10 chronic schizophrenic male patients after intravenous and oral administration. The mean equilibrium-state concentration ratio between blood and plasma was experimentally determined to be 0.87. The average values for blood clearance, hepatic extraction ratio and oral bioavailability were 250 ml/min, 0.2 and 0.27, respectively. Plasma concentration peaked on average at 3 h. The mean volume of distribution at steady-state and the terminal half-life was 1.6 l/kg and 10.3 h, respectively. A large fraction of the dose is most probably metabolized by some extrahepatic presystemic routes. The large inter-individual variability in the bioavailability and clearance is probably the main reason for large variation in the steady-state plasma level in patients receiving the same oral dosage regimen.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003984 Dibenzazepines Compounds with two BENZENE rings fused to AZEPINES.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
October 2021, The pharmacogenomics journal,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
July 2009, Yao xue xue bao = Acta pharmaceutica Sinica,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
January 1994, Psychopharmacology bulletin,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
August 1992, The American journal of psychiatry,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
October 1991, The American journal of psychiatry,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
April 2024, European journal of clinical pharmacology,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
December 2003, Journal of clinical psychopharmacology,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
August 2011, Human psychopharmacology,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
July 2000, Pharmacopsychiatry,
Y F Cheng, and T Lundberg, and U Bondesson, and L Lindström, and J Gabrielsson
December 1998, Journal of clinical psychopharmacology,
Copied contents to your clipboard!